A New Form of Glutamate Signaling Discovered in Migraine – Discovery and Innovation at University of Utah Health
Par un écrivain mystérieux
Description
Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity In Vivo
PDF) Questioning Glutamate Excitotoxicity in Acute Brain Damage: The Importance of Spreading Depolarization
A New Form of Glutamate Signaling Discovered in Migraine – Discovery and Innovation at University of Utah Health
Glutamatergic dysfunction in Schizophrenia
Frontiers Glial Cells in Glaucoma: Friends, Foes, and Potential Therapeutic Targets
The International Headache Congress – IHS and EHF joint congress 2021, The Journal of Headache and Pain
The complexities of migraine: A debate among migraine researchers: A review - ScienceDirect
American Headache Society 64th Annual Scientific Meeting June 9–12, 2022 Denver, Colorado - 2022 - Headache: The Journal of Head and Face Pain - Wiley Online Library
Controlling the Spread of Antibiotic Resistance – Discovery and Innovation at University of Utah Health
Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity In Vivo
Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity In Vivo
depuis
par adulte (le prix varie selon la taille du groupe)